Choose Your Country or Region

PKA

PKA Products

All (19)
PKA Inhibitors (14)
PKA Activators (3)
PKA Antagonist (1)
New PKA Products

Catalog No.	Product Name	Information	Product Use Citations
S1582	H 89 2HCl	H 89 2HCl is a potent PKA inhibitor with K_i of 48 nM in a cell-free assay, 10-fold selective for PKA than PKG,500-fold greater selectivity than PKC, MLCK, calmodulin kinase II and casein kinase I/II. H 89 2HCl induces autophagy.	Transl Neurodegener, 2025, 14(1):43 J Cachexia Sarcopenia Muscle, 2025, 16(3):e13853 Commun Biol, 2025, 8(1):178
S1421	Staurosporine (STS)	Staurosporine (STS) is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.	Cell Metab, 2025, S1550-4131(25)00149-4 Cell Death Dis, 2025, 16(1):396 Genes Dis, 2025, 12(3):101321
S1113	GSK690693	GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. GSK690693 also potently inhibits AMPK and DAPK3 from the CAMK family with IC50 of 50 nM and 81 nM, respectively. GSK690693 affects Unc-51-like autophagy activating kinase 1 (ULK1) activity, robustly inhibits STING-dependent IRF3 activation. Phase 1.	Front Cell Infect Microbiol, 2025, 15:1543186 Biomol Ther (Seoul), 2025, 33(1):170-181 EMBO J, 2024, 10.1038/s44318-024-00244-9
S1573	Fasudil HCl	Fasudil HCl, a potent and selective inhibitor of Rho kinase, displays less potent inhibiton over PKA, PKG, PKC and MLCK with Ki of 1.6, 1.6, 3.3, and 36 μM in cell-free assays, respectively. Fasudil is also a calcium channel blocker.	Transl Oncol, 2025, 51:102209 J Immunother Cancer, 2024, 12(11)e009805 Sci China Life Sci, 2024, 67(8):1549-1562
S7858	Dibutyryl-cAMP (Bucladesine)	Dibutyryl-cAMP (Bucladesine, dbcAMP) is a cell-permeable PKA activator by mimicing the action of endogenous cAMP. Dibutyryl-cAMP (Bucladesine) is also a phosphodiesterase (PDE) inhibitor.	Cell, 2025, S0092-8674(25)00735-4 Nat Neurosci, 2025, 28(6):1174-1184 Nat Commun, 2025, 16(1):6151
S2670	A-674563 HCl	A-674563 HCl is an Akt1 inhibitor with K_i of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.	Nat Commun, 2025, 16(1):3012 J Biol Chem, 2024, 300(2):105641 Nat Commun, 2023, 14(1):886
S7857	8-Bromo-cAMP sodium salt	8-Bromo-cAMP sodium salt is a cell permeable analog of cAMP that activates cyclic-AMP-dependent protein kinase with a Ka value of 0.05 μM; and a PKA activator.	Elife, 2024, 13RP97507 Stem Cell Res Ther, 2024, 15(1):438 Biomed Pharmacother, 2024, 176:116858
S8388	ML-7 HCl	ML-7 is an inhibitor of smooth muscle myosin light chain kinase (MLCK) with a Ki value of 0.3 µM and displays reversible, ATP-competitive inhibition of Ca2+-calmodulin-dependent and -independent smooth muscle MLCKs. ML-7 also inhibits PKA and PKC with Ki of 21 μM and 42 μM, respectively.	Cell Mol Life Sci, 2025, 82(1):201 Commun Biol, 2025, 8(1):607 J Pharmacol Sci, 2025, 158(3):172-181
S7563	AT13148	AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.	Neoplasia, 2023, 10.1016/j.neo.2023.100948 Cancers (Basel), 2022, 14(23)5943 Br J Cancer, 2021, 10.1038/s41416-021-01442-6
S2554	Daphnetin	Daphnetin, a natural coumarin derivative, is a protein kinase inhibitor, inhibits EGFR, PKA and PKC with IC50 of 7.67 μM, 9.33 μM and 25.01 μM, respectively, also known to exhibit anti-inflammatory and anti-oxidant activities.	Sci Rep, 2021, 11(1):11491 Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7 Int Immunopharmacol, 2019, 72:195-203
S0754	Bisindolylmaleimide IV	Bisindolylmaleimide IV (Arcyriarubin A, BIM IV, Compound 5/1a) is a potent inhibitor of protein kinase C (PKC) with IC50 of 0.55 μM. Bisindolylmaleimide IV also inhibits PKA with IC50 of 11.8μM. Bisindolylmaleimide IV is a potent, selective inhibitor of human cytomegalovirus (HCMV) replication in cell culture with IC50 of 0.2 μM.	Elife, 2021, 10e68473
F1294^New	Anti-PKA RI-α Rabbit Antibody [J14D6]
E4790^New	H-89	H-89 is a potent and selective inhibitor of cyclic AMP-dependent protein kinase (protein kinase A) with IC50 values of 48 nM and has weak inhibition against PKG, PKC, Casein Kinase, and other kinases.	Sci Adv, 2025, 11(23):eadt3552
E7109^New	PKI(5-24)	PKI(5-24) is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase), with a Ki of 2.3 nM. It can be used for research to study hormonal regulation of the CAMP-dependent protein kinase.
E4793^New	Bucladesine calcium	Bucladesine calcium (Dibutyryl-cAMP Calcium Salt, DBcAMP calcium salt) is a cell-permeable analog of cyclic AMP. It serves as a potent activator of protein kinase A (PKA) and mimics the effects of endogenous cAMP. It also inhibits phosphodiesterase (PDE) activity, with the potential to treat congestive heart failure, wound healing, and inflammation.
E7359^New	A-674563	A-674563 is a selective, orally active inhibitor of Akt1 with a Ki of 11 nM. It also inhibits PKA with Ki of 16 nM and CDK2 with Ki of 46 nM. A-674563 reduces Akt downstream target phosphorylation and inhibits tumor cell proliferation in vitro with an EC50 of 0.4 µM.
E2506	A-3 hydrochloride	A-3 hydrochloride, a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases, againsts cAMP-dependent protein kinase (PKA) (Ki=4.3 µM), casein kinase II (CK2) (Ki=5.1 µM) and myosin light chain kinase (MLCK) (Ki=7.4 µM), also inhibits Protein Kinase C (PKC) and casein kinase I (CK1) with Ki values of 47 µM and 80 µM, respectively.
S6214	H-1152 dihydrochloride	H-1152 dihydrochloride (2HCl) is a membrane-permeable and selective inhibitor of Rho-associated protein kinase (ROCK). H-1152 inhibits ROCK2, PKA, PKC, PKG, AuroraA and CaMK2 with IC50 of 0.0120 μM, 3.03 μM, 5.68 μM, 0.360 μM, 0.745 μM and 0.180 μM, respectively.
S2964	HA-100 dihydrochloride	HA-100 dihydrochloride is an inhibitor of cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase with IC50 of 4 μM, 8 μM, 12 μM and 240 μM, respectively.	Adv Sci (Weinh), 2024, 11(4):e2304987
S1582	H 89 2HCl	H 89 2HCl is a potent PKA inhibitor with K_i of 48 nM in a cell-free assay, 10-fold selective for PKA than PKG,500-fold greater selectivity than PKC, MLCK, calmodulin kinase II and casein kinase I/II. H 89 2HCl induces autophagy.	Transl Neurodegener, 2025, 14(1):43 J Cachexia Sarcopenia Muscle, 2025, 16(3):e13853 Commun Biol, 2025, 8(1):178
S1421	Staurosporine (STS)	Staurosporine (STS) is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.	Cell Metab, 2025, S1550-4131(25)00149-4 Cell Death Dis, 2025, 16(1):396 Genes Dis, 2025, 12(3):101321
S1113	GSK690693	GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. GSK690693 also potently inhibits AMPK and DAPK3 from the CAMK family with IC50 of 50 nM and 81 nM, respectively. GSK690693 affects Unc-51-like autophagy activating kinase 1 (ULK1) activity, robustly inhibits STING-dependent IRF3 activation. Phase 1.	Front Cell Infect Microbiol, 2025, 15:1543186 Biomol Ther (Seoul), 2025, 33(1):170-181 EMBO J, 2024, 10.1038/s44318-024-00244-9
S1573	Fasudil HCl	Fasudil HCl, a potent and selective inhibitor of Rho kinase, displays less potent inhibiton over PKA, PKG, PKC and MLCK with Ki of 1.6, 1.6, 3.3, and 36 μM in cell-free assays, respectively. Fasudil is also a calcium channel blocker.	Transl Oncol, 2025, 51:102209 J Immunother Cancer, 2024, 12(11)e009805 Sci China Life Sci, 2024, 67(8):1549-1562
S2670	A-674563 HCl	A-674563 HCl is an Akt1 inhibitor with K_i of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.	Nat Commun, 2025, 16(1):3012 J Biol Chem, 2024, 300(2):105641 Nat Commun, 2023, 14(1):886
S8388	ML-7 HCl	ML-7 is an inhibitor of smooth muscle myosin light chain kinase (MLCK) with a Ki value of 0.3 µM and displays reversible, ATP-competitive inhibition of Ca2+-calmodulin-dependent and -independent smooth muscle MLCKs. ML-7 also inhibits PKA and PKC with Ki of 21 μM and 42 μM, respectively.	Cell Mol Life Sci, 2025, 82(1):201 Commun Biol, 2025, 8(1):607 J Pharmacol Sci, 2025, 158(3):172-181
S7563	AT13148	AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.	Neoplasia, 2023, 10.1016/j.neo.2023.100948 Cancers (Basel), 2022, 14(23)5943 Br J Cancer, 2021, 10.1038/s41416-021-01442-6
S2554	Daphnetin	Daphnetin, a natural coumarin derivative, is a protein kinase inhibitor, inhibits EGFR, PKA and PKC with IC50 of 7.67 μM, 9.33 μM and 25.01 μM, respectively, also known to exhibit anti-inflammatory and anti-oxidant activities.	Sci Rep, 2021, 11(1):11491 Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7 Int Immunopharmacol, 2019, 72:195-203
S0754	Bisindolylmaleimide IV	Bisindolylmaleimide IV (Arcyriarubin A, BIM IV, Compound 5/1a) is a potent inhibitor of protein kinase C (PKC) with IC50 of 0.55 μM. Bisindolylmaleimide IV also inhibits PKA with IC50 of 11.8μM. Bisindolylmaleimide IV is a potent, selective inhibitor of human cytomegalovirus (HCMV) replication in cell culture with IC50 of 0.2 μM.	Elife, 2021, 10e68473
E4790^New	H-89	H-89 is a potent and selective inhibitor of cyclic AMP-dependent protein kinase (protein kinase A) with IC50 values of 48 nM and has weak inhibition against PKG, PKC, Casein Kinase, and other kinases.	Sci Adv, 2025, 11(23):eadt3552
E7109^New	PKI(5-24)	PKI(5-24) is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase), with a Ki of 2.3 nM. It can be used for research to study hormonal regulation of the CAMP-dependent protein kinase.
E7359^New	A-674563	A-674563 is a selective, orally active inhibitor of Akt1 with a Ki of 11 nM. It also inhibits PKA with Ki of 16 nM and CDK2 with Ki of 46 nM. A-674563 reduces Akt downstream target phosphorylation and inhibits tumor cell proliferation in vitro with an EC50 of 0.4 µM.
S6214	H-1152 dihydrochloride	H-1152 dihydrochloride (2HCl) is a membrane-permeable and selective inhibitor of Rho-associated protein kinase (ROCK). H-1152 inhibits ROCK2, PKA, PKC, PKG, AuroraA and CaMK2 with IC50 of 0.0120 μM, 3.03 μM, 5.68 μM, 0.360 μM, 0.745 μM and 0.180 μM, respectively.
S2964	HA-100 dihydrochloride	HA-100 dihydrochloride is an inhibitor of cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase with IC50 of 4 μM, 8 μM, 12 μM and 240 μM, respectively.	Adv Sci (Weinh), 2024, 11(4):e2304987
S7858	Dibutyryl-cAMP (Bucladesine)	Dibutyryl-cAMP (Bucladesine, dbcAMP) is a cell-permeable PKA activator by mimicing the action of endogenous cAMP. Dibutyryl-cAMP (Bucladesine) is also a phosphodiesterase (PDE) inhibitor.	Cell, 2025, S0092-8674(25)00735-4 Nat Neurosci, 2025, 28(6):1174-1184 Nat Commun, 2025, 16(1):6151
S7857	8-Bromo-cAMP sodium salt	8-Bromo-cAMP sodium salt is a cell permeable analog of cAMP that activates cyclic-AMP-dependent protein kinase with a Ka value of 0.05 μM; and a PKA activator.	Elife, 2024, 13RP97507 Stem Cell Res Ther, 2024, 15(1):438 Biomed Pharmacother, 2024, 176:116858
E4793^New	Bucladesine calcium	Bucladesine calcium (Dibutyryl-cAMP Calcium Salt, DBcAMP calcium salt) is a cell-permeable analog of cyclic AMP. It serves as a potent activator of protein kinase A (PKA) and mimics the effects of endogenous cAMP. It also inhibits phosphodiesterase (PDE) activity, with the potential to treat congestive heart failure, wound healing, and inflammation.
E2506	A-3 hydrochloride	A-3 hydrochloride, a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases, againsts cAMP-dependent protein kinase (PKA) (Ki=4.3 µM), casein kinase II (CK2) (Ki=5.1 µM) and myosin light chain kinase (MLCK) (Ki=7.4 µM), also inhibits Protein Kinase C (PKC) and casein kinase I (CK1) with Ki values of 47 µM and 80 µM, respectively.
F1294^New	Anti-PKA RI-α Rabbit Antibody [J14D6]
E4790^New	H-89	H-89 is a potent and selective inhibitor of cyclic AMP-dependent protein kinase (protein kinase A) with IC50 values of 48 nM and has weak inhibition against PKG, PKC, Casein Kinase, and other kinases.	Sci Adv, 2025, 11(23):eadt3552
E7109^New	PKI(5-24)	PKI(5-24) is a potent, competitive, and synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase), with a Ki of 2.3 nM. It can be used for research to study hormonal regulation of the CAMP-dependent protein kinase.
E4793^New	Bucladesine calcium	Bucladesine calcium (Dibutyryl-cAMP Calcium Salt, DBcAMP calcium salt) is a cell-permeable analog of cyclic AMP. It serves as a potent activator of protein kinase A (PKA) and mimics the effects of endogenous cAMP. It also inhibits phosphodiesterase (PDE) activity, with the potential to treat congestive heart failure, wound healing, and inflammation.
E7359^New	A-674563	A-674563 is a selective, orally active inhibitor of Akt1 with a Ki of 11 nM. It also inhibits PKA with Ki of 16 nM and CDK2 with Ki of 46 nM. A-674563 reduces Akt downstream target phosphorylation and inhibits tumor cell proliferation in vitro with an EC50 of 0.4 µM.

Choose Selective PKA Inhibitors